文献速递胸部肿瘤放疗

局部晚期肺癌根治性放化疗患者无细胞循环肿瘤DNA无创分子分析

Cell-Free Circulating Tumor DNA for NonInvasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-02-02

该前瞻性临床队列研究纳入25例不可切除局部晚期NSCLC患者,在治疗前进行液体活检ctDNA检测,探索其作为根治性放化疗预后和预测生物标志物的效用。

要点

  • ctDNA检出与治疗前FDG-PET SUV指标显著相关,整合突变数后关联增强。

核心结论

  • 根治性放化疗患者前瞻性液体活检可识别驱动基因变异和放疗反应标志物,对治疗个体化有直接意义。

研究设计与样本

  • 前瞻性临床队列纳入25例不可切除局部晚期NSCLC患者,治疗前进行液体活检检测。
  • 液体活检使用包含129个基因的机构检测方法及配对白细胞测序。
  • 变异等位基因频率定义为特定基因位点突变等位基因的比例,使用OncoKB数据库分类变异。
  • 从放疗开始计算无进展生存期,采用log-rank检验评估。

主要发现

  • 25例患者中腺癌18例(72%),鳞癌7例(28%), former或当前吸烟者23例(92%)。
  • 12例(48%)接受辅助durvalumab治疗,中位放疗剂量60 Gy/30次(范围55-66 Gy/20-33次)。
  • 最常见的驱动变异为KRAS突变,占队列24%(n=6)。

关键数值与推荐

  • ctDNA检出与治疗前18F-FDG PET SUV指标显著相关,整合突变数作为结局变量后关联增强。

临床怎么用

  • 治疗前液体活检可检出驱动变异和放疗反应标志物,可能有助于治疗个体化。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We prospectively explored the utility of liquid biopsy for cell-free circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with definitive chemoradiation therapy. METHODS AND MATERIALS: This prospective clinical cohort consisted of patients with unresectable, locally advanced NSCLC who had liquid biopsy testing before initiation of cancer therapy. Liquid biopsy testing was performed using an institutional assay that included 129 genes and paired white blood cell sequencing. Variant allele frequency was defined as the proportion of mutant alleles at a particular genetic locus. A US Food and Drug Administration-recognized database (OncoKB) was used to classify alterations. We evaluated progression-free survival from the start of radiation therapy using the log-rank test. RESULTS: Among 25 patients with prospective testing of ctDNA levels before therapy initiation, 18 patients had adenocarcinoma (72%), 7 patients had squamous cell carcinoma (28%), and 23 (92%) were former or current smokers. Twelve patients (48%) received adjuvant durvalumab. The median radiation dose was 60 Gy in 30 fractions (range, 55-66 Gy in 20-33 fractions). Seventy-six percent of patients (n = 18) had one or more alterations detected (median, 3 alterations, range, 1-8), including genomic markers of radiation response in 3 patients. The most common driver alteration detected was KRAS mutation in 24% of the cohort (n = 6). The detection of ctDNA levels was significantly associated with pretreatment 18F-fluorodeoxyglucose positron emission tomography standardized uptake value metrics, and the association was strengthened by integrating the number of mutations (compared with variant allele frequency) as the outcome variable. Among patients with baseline detectable ctDNA levels, the median progression-free survival was 21.3 months and was not reached among patients without baseline ctDNA level detection (hazard ratio, 4.54, P = .04). CONCLUSIONS: Prospective liquid biopsy testing among patients treated with definitive chemoradiation therapy identifies driver alterations and markers of radiation response with direct implications for therapy personalization.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lebow ES, Eichholz J, Boe L, et al. Cell-Free Circulating Tumor DNA for NonInvasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung Cancer. Adv Radiat Oncol. 2025. PMID: 40213312. doi:10.1016/j.adro.2025.101727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。